Randomized Controlled Trial

. 2023 Dec 20;228(12):1662-1666.

doi: 10.1093/infdis/jiad323.

Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

Nadine G Rouphael¹, Angela R Branche², David J Diemert³, Ann R Falsey², Cecilia Losada¹, Lindsey R Baden⁴, Sharon E Frey⁵, Jennifer A Whitaker⁶, Susan J Little⁷, Satoshi Kamidani^{8

9}, Emmanuel B Walter¹⁰, Richard M Novak¹¹, Richard Rupp¹², Lisa A Jackson¹³, Tara M Babu¹⁴, Angelica C Kottkamp¹⁵, Anne F Luetkemeyer¹⁶, Lilly C Immergluck¹⁷, Rachel M Presti¹⁸, Martín Bäcker¹⁹, Patricia L Winokur²⁰, Siham M Mahgoub²¹, Paul A Goepfert²², Dahlene N Fusco²³, Robert L Atmar⁶, Christine M Posavad^{24

25}, Antonia Netzl²⁶, Derek J Smith²⁶, Kalyani Telu²⁷, Jinjian Mu²⁷, Lisa J McQuarrie²⁷, Mat Makowski²⁷, Mamodikoe K Makhene²⁸, Sonja Crandon²⁸, David C Montefiori²⁹, Paul C Roberts²⁸, John H Beigel²⁸; Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team

Collaborators, Affiliations

Collaborators

Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team:
David J Diemert, Elissa Malkin, Jeffrey M Bethony, Aimee Desrosiers, Marc Siegel, Angela R Branche, Ann R Falsey, Edward Walsh, Patrick Kingsley, Michael Peasley, Nadine G Rouphael, Cecilia Losada, Daniel S Graciaa, Hady Samaha, Paulina A Rebolledo, Zanthia Wiley, Lindsey R Baden, Amy C Sherman, Stephen R Walsh, Alexandra Tong, Rebecca Rooks, Sharon E Frey, Getahun Abate, Zacharoula Oikonomopoulou, Daniel F Hoft, Irene Graham, Jennifer A Whitaker, Hana M El Sahly, Wendy A Keitel, C Mary Healy, Robert L Atmar, Susan J Little, Thomas C S Martin, Nicole Carter, Steven Hendrickx, Evan J Anderson, Christina A Rostad, Satoshi Kamidani, Etza Peters, Emmanuel B Walter, Michael J Smith, M Anthony Moody, Kenneth E Schmader, Richard M Novak, Benjamin G Ladner, Andrea Wendrow, Jessica Herrick, Richard Rupp, Laura Porterfield, Lisa A Jackson, Maya Dunstan, Rebecca Lau, Barbara Carste, Tara M Babu, Anna Wald, Taylor Krause, Kirsten Hauge, Angelica C Kottkamp, Mark J Mulligan, Tamia Davis, Celia Engelson, Vijaya Soma, Anne F Luetkemeyer, Chloe Harris, Azquena Munoz Lopez, Lilly C Immergluck, Erica Johnson, Austin Chan, Rachel M Presti, Jane A O'Halloran, Ryley M Thompson, Martín Bäcker, Andrew B Fleming, Sajumon Joseph, Patricia L Winokur, Jeffery Meier, Jack Stapleton, Siham M Mahgoub, Celia Maxwell, Sarah Shami, Paul A Goepfert, Dahlene N Fusco, Arnaud C Drouin, Florice K Numbi, Kirsten E Lyke, David S Stephens, Kathleen M Neuzil, Monica M Farley, Jeanne Marrazzo, Sidnee Paschal Young, Jeffery Lennox, Robert L Atmar, Linda McNeil, Elizabeth Brown, Christine M Posavad, Megan A Meagher, Julie McElrath, Mike Gale, Kuleni Abebe, Mat Makowski, Heather Hill, Jim Albert, Holly Baughman, Lisa McQuarrie, Kalyani Telu, Jinjian Mu, Lisa J McQuarrie, Teri C Lewis, Lisa A Giebeig, Theresa M Engel, Caleb J Griffith, Wendi L McDonald, Alissa E Burkey, Lisa B Hoopengardner, Jessica E Linton, Nikki L Gettinger, David C Montefiori, Amanda Eaton, Derek J Smith, Antonia Netzl, Samuel H Wilks, Sina Türeli, Mamodikoe Makhene, Mohamed Elsafy, Rhonda Pikaart-Tautges, Janice Arega, Binh Hoang, Dan Curtin, Hyung Koo, Elisa Sindall, Sonja Crandon, Marciela M DeGrace, Diane J Post, Seema U Nayak, Paul C Roberts, John H Beigel

Affiliations

¹ Hope Clinic, Emory University, Decatur, Georgia.
² Vaccine and Treatment Evaluation Unit, University of Rochester, New York.
³ George Washington Vaccine Research Unit, George Washington University, Washington, District of Columbia.
⁴ Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
⁵ Center for Vaccine Development, Saint Louis University, Missouri.
⁶ Department of Molecular Virology and Microbiology and Department of Medicine, Baylor College of Medicine, Houston, Texas.
⁷ Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla.
⁸ Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta.
⁹ Department of Pediatrics, Emory University, Atlanta, Georgia.
¹⁰ Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
¹¹ Project WISH, University of Illinois at Chicago, Chicago, Illinois.
¹² Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas.
¹³ Kaiser Permanente Washington Health Research Institute, Seattle, Washington.
¹⁴ Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington.
¹⁵ Vaccine and Treatment Evaluation Unit, Manhattan Research Clinic, New York University Grossman School of Medicine, New York, New York.
¹⁶ Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, California.
¹⁷ Clinical Research Center, Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, Georgia.
¹⁸ Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
¹⁹ Vaccine and Treatment Evaluation Unit, Long Island Research Clinic, New York University Long Island School of Medicine, Mineola, New York.
²⁰ Department of Medicine, University of Iowa College of Medicine, Iowa City, Iowa.
²¹ Howard University College of Medicine, Howard University Hospital, Washington, District of Columbia.
²² Department of Medicine, University of Alabama at Birmingham, Alabama.
²³ Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana.
²⁴ Infectious Diseases Clinical Research Consortium (IDCRC) Laboratory Operations Unit, Fred Hutchinson Cancer Center, Seattle, Washington.
²⁵ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.
²⁶ Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, United Kingdom.
²⁷ The Emmes Company, LLC, Rockville, Maryland.
²⁸ Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
²⁹ Department of Surgery, Duke University, Durham, North Carolina.

PMID: 37561027
PMCID: PMC11032204
DOI: 10.1093/infdis/jiad323

Randomized Controlled Trial

Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

Nadine G Rouphael et al. J Infect Dis. 2023.

. 2023 Dec 20;228(12):1662-1666.

doi: 10.1093/infdis/jiad323.

Authors

Collaborators

Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team:
David J Diemert, Elissa Malkin, Jeffrey M Bethony, Aimee Desrosiers, Marc Siegel, Angela R Branche, Ann R Falsey, Edward Walsh, Patrick Kingsley, Michael Peasley, Nadine G Rouphael, Cecilia Losada, Daniel S Graciaa, Hady Samaha, Paulina A Rebolledo, Zanthia Wiley, Lindsey R Baden, Amy C Sherman, Stephen R Walsh, Alexandra Tong, Rebecca Rooks, Sharon E Frey, Getahun Abate, Zacharoula Oikonomopoulou, Daniel F Hoft, Irene Graham, Jennifer A Whitaker, Hana M El Sahly, Wendy A Keitel, C Mary Healy, Robert L Atmar, Susan J Little, Thomas C S Martin, Nicole Carter, Steven Hendrickx, Evan J Anderson, Christina A Rostad, Satoshi Kamidani, Etza Peters, Emmanuel B Walter, Michael J Smith, M Anthony Moody, Kenneth E Schmader, Richard M Novak, Benjamin G Ladner, Andrea Wendrow, Jessica Herrick, Richard Rupp, Laura Porterfield, Lisa A Jackson, Maya Dunstan, Rebecca Lau, Barbara Carste, Tara M Babu, Anna Wald, Taylor Krause, Kirsten Hauge, Angelica C Kottkamp, Mark J Mulligan, Tamia Davis, Celia Engelson, Vijaya Soma, Anne F Luetkemeyer, Chloe Harris, Azquena Munoz Lopez, Lilly C Immergluck, Erica Johnson, Austin Chan, Rachel M Presti, Jane A O'Halloran, Ryley M Thompson, Martín Bäcker, Andrew B Fleming, Sajumon Joseph, Patricia L Winokur, Jeffery Meier, Jack Stapleton, Siham M Mahgoub, Celia Maxwell, Sarah Shami, Paul A Goepfert, Dahlene N Fusco, Arnaud C Drouin, Florice K Numbi, Kirsten E Lyke, David S Stephens, Kathleen M Neuzil, Monica M Farley, Jeanne Marrazzo, Sidnee Paschal Young, Jeffery Lennox, Robert L Atmar, Linda McNeil, Elizabeth Brown, Christine M Posavad, Megan A Meagher, Julie McElrath, Mike Gale, Kuleni Abebe, Mat Makowski, Heather Hill, Jim Albert, Holly Baughman, Lisa McQuarrie, Kalyani Telu, Jinjian Mu, Lisa J McQuarrie, Teri C Lewis, Lisa A Giebeig, Theresa M Engel, Caleb J Griffith, Wendi L McDonald, Alissa E Burkey, Lisa B Hoopengardner, Jessica E Linton, Nikki L Gettinger, David C Montefiori, Amanda Eaton, Derek J Smith, Antonia Netzl, Samuel H Wilks, Sina Türeli, Mamodikoe Makhene, Mohamed Elsafy, Rhonda Pikaart-Tautges, Janice Arega, Binh Hoang, Dan Curtin, Hyung Koo, Elisa Sindall, Sonja Crandon, Marciela M DeGrace, Diane J Post, Seema U Nayak, Paul C Roberts, John H Beigel

Affiliations

¹ Hope Clinic, Emory University, Decatur, Georgia.
² Vaccine and Treatment Evaluation Unit, University of Rochester, New York.
³ George Washington Vaccine Research Unit, George Washington University, Washington, District of Columbia.
⁴ Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
⁵ Center for Vaccine Development, Saint Louis University, Missouri.
⁶ Department of Molecular Virology and Microbiology and Department of Medicine, Baylor College of Medicine, Houston, Texas.
⁷ Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla.
⁸ Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta.
⁹ Department of Pediatrics, Emory University, Atlanta, Georgia.
¹⁰ Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina.
¹¹ Project WISH, University of Illinois at Chicago, Chicago, Illinois.
¹² Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas.
¹³ Kaiser Permanente Washington Health Research Institute, Seattle, Washington.
¹⁴ Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington.
¹⁵ Vaccine and Treatment Evaluation Unit, Manhattan Research Clinic, New York University Grossman School of Medicine, New York, New York.
¹⁶ Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, California.
¹⁷ Clinical Research Center, Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, Georgia.
¹⁸ Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
¹⁹ Vaccine and Treatment Evaluation Unit, Long Island Research Clinic, New York University Long Island School of Medicine, Mineola, New York.
²⁰ Department of Medicine, University of Iowa College of Medicine, Iowa City, Iowa.
²¹ Howard University College of Medicine, Howard University Hospital, Washington, District of Columbia.
²² Department of Medicine, University of Alabama at Birmingham, Alabama.
²³ Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana.
²⁴ Infectious Diseases Clinical Research Consortium (IDCRC) Laboratory Operations Unit, Fred Hutchinson Cancer Center, Seattle, Washington.
²⁵ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.
²⁶ Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, United Kingdom.
²⁷ The Emmes Company, LLC, Rockville, Maryland.
²⁸ Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
²⁹ Department of Surgery, Duke University, Durham, North Carolina.

PMID: 37561027
PMCID: PMC11032204
DOI: 10.1093/infdis/jiad323

Abstract

We compared the serologic responses of 1 dose versus 2 doses of a variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults. A 2-dose boosting regimen with a variant vaccine did not increase the magnitude or the durability of the serological responses compared to a single variant vaccine boost.

Keywords: SARS-CoV-2; vaccine; variant.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. A. R. B. has received research support from NIH-NIAID, grants from Pfizer, Cyanvac, Moderna, Vaccine.co and Merck as well as consulting fees from Janssen and GSK. She serves as DSMB member for NIH, IDSA Public Health Committee. Honoraria as a speaker from Virology Education. L. R. B. has received grants from Wellcome Trust, Gates Foundation, NIH/Harvard Medical School through institution. Serves as member of DSMB for NIH and AMDAC for FDA. Dr Baden is involved in HIV and SARS-CoV-2 vaccine clinical trials conducted in collaboration with the NIH, HIV Vaccine Trials Network (HVTN), Covid Vaccine Prevention Network (CoVPN), International AIDS Vaccine Initiative (IAVI), Crucell/Janssen, Moderna, Military HIV Research Program (MHRP), the Gates Foundation, and Harvard Medical School. D. J. D. has received a contract from Leidos Biomedical/NIH research to conduct the clinical trial through institution. A. R. F. has received grants from Janssen, Pfizer, Merck, BioFire Diagnostics, Moderna, Vaccine company and CyanVac through institution. Consultant fees from Arrow Pharmaceutical, ADMA biologics, GSK, and honoraria as a speaker from Sanofi and GlaxoSmithKline. Serves as DSMB advisory boards for Novavax and received travel/meeting support from GlaxoSmithKline. S. E. F. has received funding from Leidos to Saint Louis University to conduct Protocol DMID 22-0004. Funding was also received to conduct the Moderna and Janssen trials phase 3 SARS-CoV-2 trials. Serves as DSMB for HVTN Safety Monitoring Board. D. N. F. has as a contract from CDC and is the site PI for DN Fusco study of COVID in Special Populations. D. N. F. served on an HBV Advisory board for Gilead related to hepatitis C & B viruses and Axcella related to Long COVID. P. A. G. has received funding from NIH. PAG has a patent for COVID-19 monoclonal not developed clinically and received consulting fees from International AIDS Society as speaker. L. C. I. has received support from NIH, Moderna, Pfizer, and Sanofi. L. C. I. has also received grants from GSK, Merck, Sharpe & Dohme Corp, CDC, Novavax, Pediatric Emergency Medicine Associates, and NIH/NLM/National Institute on Minority Health and Health Disparities as well as consulting fees from Moderna. L. C. I. has received honoraria as a speaker from American Academy of Pediatrics, Rockefeller University, Moderna, CDC and American Academy of Pediatrics- Georgia Chapter. L. C. I. Serves on Data Safety Monitoring for NIH-Phase 2 Vaccine Trial for Monkeypox, Moderna Scientific Advisory Board- North America, and CoVID-19 Task Force, Georgia. L. C. I. has a leadership role Break the Cycle of Health Disparities Inc, the Center for Spatial Analytics of the Georgia Institute of Technology, and the American Academy of Pediatrics (Executive Board for Section on Infectious Diseases). L. C. I. has received travel/meeting support from the American Academy of Pediatrics and Moderna. L. A. J. has received funding from NIH for support for this study, funding from Pfizer to support a clinical trial and contract funding for research support from the CDC and the NIH, all through institution. L. A. J. also reports unpaid participation on Data Safety Monitoring Boards for NIH funded clinical trials. S. K. has received research grants from NIH, Pfizer, U.S. Centers for Disease Control and Prevention, Meisa, Emergent BioSolutions. S. K. also received support from American Academy of Pediatrics as speaker. A. C. K. has received research support from COVID-19 Adaptive Variance Immunologic Landscape Trial # 28C15000NYUPG266894. S. J. L. has received NIH grants through institution. Consulting fees from Hookipa Pharma. A. F. L. has received grants from Merck, Gilead and, GSK through institution as well as consulting fees from Vir Biotechnology. A. F. L. has also received travel support from Merck to attend a required investigator meeting, testing kits and supplies to support research study from Hologic, Cepheid and medication donated by Mayne Pharma to support research study. M. M. has received funding from Emmes through NIH contract # HHSN272201500002C. L. J. M. has received funding from Emmes through NIH contract # HHSN272201500002C. D. C. M. has received funding from NIH/75N93019C00050-21A: CIVICS A- Option 21A-DMID Trials of COVID-19 Vaccines. J. M. has received funding from Division of Microbiology and Infectious Diseases, contract # 75N93021C00012. A. N. has received support from NIH-NIAID, CEIRR (Centers of Excellence for Influenza Research and Response) and Gates Cambridge Trust as well as grants from NIH-NIAID R01. R. M. N. has received grants from NIAID-DMID and travel/meeting support from Moderna. C. M. P. has received funding from NIAID UM1AI148684. R. M. P. has received funding from NIH DMID COVAIL as well as grants from Janssen, Moderna and NIH through institution. N. G. R. has received research grants from NIH, Pfizer, Merck, Sanofi, Quidel, Immorna, Vaccine Company and Lilly through her institution, consulting fees from Krog, honoraria as speaker for Virology education, and travel support from Sanofi and Moderna. N. G. R. serves as DSMB on safety committees for ICON, Micron and EMMES and is a member of the Moderna, Sanofi, Seqirus and Pfizer selected Advisory boards. Plays leadership advisory role for ARLG, TMRC, CDC-Pertussis challenge, Clinical Infectious Diseases. Equipment supports from Georgia Research Alliance. D. J. S. has received support from NIH-NIAID CEIRR, grants from NIH-NIAID R01, and travel support from NIH-NIAID CEIRR for NIH-related meetings. K. T. has received funding from Emmes through NIH contract # HHSN272201500002C. E. B. W. has received funding from Leidos Biomedical Research AGREEMENT NO. 22CTA-DM0009 as well as grants from Pfizer, Moderna, Sequiris, Clinetic, and Najit Technologies, with payments made to institution. E. B. W. has also received honoraria as a speaker from College of Diplomates of the American Board of Pediatric Dentistry, consulting fees from Iliad Biotechnologies, and travel/meeting support from the American Academy of Pediatrics. E. B. W. serves as member of Vaxcyte Scientific Advisory board. P. L. W. has received subcontract funding from NIH for this study as well as NIH grant funding and contract funding from Pfizer through University of Iowa. P. L. W. has also received consulting fees from Pfizer and serves on DSMB advisory board for Emmes Corporation, Blue Lake. M. B. has received research grants from Leidos Biomedical Research and Pfizer through institution. J. A. W. has received funding from NIH-DMID 75N91019D00024. R. L. A., T. M. B., S. M. M., M. K. M., J. H. B., S. C., C. L., P. C. R., R. R. authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

**Figure 1.**
Pseudovirus neutralization serum inhibitory dilutions required for 50% neutralization (ID₅₀) titers by timepoint (baseline and days 15, 29, 91, and 181 for the 1-dose arm and days 15, 29, 57 [prior to receipt of the second dose], 85 [28 days after the second dose], 147 [90 days after the second dose], and 237 [180 days after the second dose] for the 2-dose arm) and variants (D614G, Omicron BA.1 [B.1.1.529], BA.4/BA.5, Beta [B.1.351], and Delta [B.1.617.2]) before and after vaccination with 1 dose of 50 μg of Moderna mRNA-1273 Beta/Omicron BA.1 (A) or 2 doses (given 56 days apart) of 50 μg Moderna mRNA-1273 Beta/Omicron BA.1 (B) in participants previously uninfected at baseline. Boxes with horizontal bars denote interquartile range and median ID₅₀, respectively. Whisker denotes 95% confidence interval. Abbreviations: GMFD, geometric mean fold decrease from baseline; GMFR, geometric mean fold rise from baseline; GMR, geometric mean ratio (relative to D614G); GMT, geometric mean titer; ID₅₀, serum inhibitory dilution required for 50% neutralization; LLOD, lower limit of detection of the assay.

See this image and copyright information in PMC

Update of

Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.
Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Netzl A, Smith DJ, Telu K, Mu J, Makowski M, Makhene MK, Crandon S, Montefiori DC, Roberts PC, Beigel JH. Rouphael NG, et al. medRxiv [Preprint]. 2023 Jun 10:2023.06.06.23290973. doi: 10.1101/2023.06.06.23290973. medRxiv. 2023. Update in: J Infect Dis. 2023 Dec 20;228(12):1662-1666. doi: 10.1093/infdis/jiad323. PMID: 37333252 Free PMC article. Updated. Preprint.

References

1. Branche AR, Rouphael NG, Diemert DJ, et al. SARS-CoV-2 Variant Vaccine Boosters Trial: preliminary analyses. medRxiv [Preprint]. Posted online 15 July 2022. doi:10.1101/2022.07.12.22277336 - DOI
1. US Food and Drug Administration . Coronavirus (COVID-19) update: FDA authorizes second booster dose of two COVID-19 vaccines for older and immunocompromised individuals. 2022. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19.... Accessed 9 August 2023.
1. US Food and Drug Administration . Updated COVID-19 vaccines for use in the United States beginning in fall 2023. 2023. Available at: https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-u.... Accessed 21 July 2023.
1. Atmar RL, Lyke KE, Deming ME, et al. Homologous and heterologous COVID-19 booster vaccinations. N Engl J Med 2022; 386:1046–57. - PMC - PubMed
1. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2022; 375:43–50. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

Collaborators

Affiliations

Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

Figures

Update of

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous